Candel Gets FDA Fast-Track Designation for CAN-3110 in Recurrent High-Grade Glioma

By Colin Kellaher

Candel Therapeutics has won U.S. Food and Drug Administration fast-track designation for its CAN-3110 drug candidate in an aggressive brain tumor.

The Needham, Mass., clinical-stage biopharmaceutical company on Tuesday said the designation covers CAN-3110 for the treatment of patients with recurrent high-grade glioma to improve overall survival.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

02-13-24 0803ET